

# Week 10: Deliverables

**Group Name:** Medical Data Science

**Name:** Peter Abban

**Email:** [abbanpeter12@gmail.com](mailto:abbanpeter12@gmail.com)

**Country:** Hungary

**Specialization:** Data Science

## ❖ Problem Description

A critical challenge for pharmaceutical companies is **understanding and monitoring drug persistency**, which reflects the extent to which patients adhere to prescribed medication schedules over time. Poor adherence compromises treatment efficacy, increases healthcare costs, and negatively impacts patient outcomes.


To address this challenge, **ABC Pharmaceutical Company engaged an analytics firm** to develop an automated system based on some feature variables of the patients

By leveraging advanced analytics, the solution aims to enhance **patient care, support physicians in monitoring compliance, and inform strategic decisions for the company's pharmaceutical portfolio** by making predictions on whether the patient is persistent or non-persistent


## ❖ Exploratory Data Analysis on the Dataset

### 1. Introduction


This analysis investigates patterns of drug persistency and non-persistency among patients based on demographic, clinical, and behavioral variables. Bar plots were generated to illustrate the distribution of persistent and non-persistent patients across several categorical features, including Gender, Race, Ethnicity, Region, Age\_Bucket, Ntm\_Speciality\_Bucket, Risk\_Segment\_Prior\_Ntm, Tscore\_Bucket\_Prior\_Ntm, Risk\_Segment\_During\_Rx, Tscore\_Bucket\_During\_Rx, Adherent\_Flag, and Injectable\_Experience\_During\_Rx. The following are the figures of the selected categories plotted with the persistency flag.




**Figure 1.** Plot of Gender with Persistency flag




**Figure 2.** Plot of Race with Persistency flag




**Figure 3.** Plot of Ethnicity with Persistency flag




**Figure 4.** Plot of Region with Persistency flag




**Figure 5.** Plot of Age\_Bucket with Persistency flag




**Figure 6.** Plot of Ntm\_Speciality with Persistency flag




**Figure 7.** Plot of Risk\_Segment\_Prior\_Ntm with Persistency flag




**Figure 8.** Plot of Tscore\_Bucket\_Prior\_Ntm with Persistency flag




**Figure 9.** Plot of Risk\_Segment\_During\_Rx with Persistency flag



**Figure 10.** Plot of Tscore\_Bucket\_During\_Rx with Persistency flag



**Figure 11.** Plot of Adherent flag with Persistency flag



**Figure 12.** Plot of Injectable\_Experience\_During\_Rx with Persistency flag

## 2. Key Observations

### a. Demographic Patterns


- **Gender:** Female patients represent the majority across all categories, with a higher proportion of non-persistent cases.
- **Race:** Caucasian patients show the highest representation, again with elevated non-persistence rates.
- **Ethnicity:** Non-Hispanic individuals display the largest patient count and the highest non-persistence levels.
- **Region:** The Midwest records the highest number of non-persistent cases.
- **Age\_Bucket:** Patients aged 75 years and above exhibit the greatest non-persistence, suggesting age-related adherence challenges.

### b. Clinical and Risk Factors


- **Ntm\_Speciality\_Bucket:** OB/GYN and other specialties show the highest counts for both persistence and non-persistence.
- **Risk\_Segment\_Prior\_Ntm:** The VLR\_LR (Very Low Risk–Low Risk) group has the largest count for both persistence flag outcomes.
- **Tscore\_Bucket\_During\_Rx:** Patients with T-scores  $\leq -2.5$  dominate both persistent and non-persistent groups.
- **Adherent\_Flag:** The Adherent group shows the highest counts overall, yet includes many non-persistent cases.
- **Injectable\_Experience\_During\_Rx:** Patients with prior injectable experience (Y) have the highest counts, with non-persistence also prominent.

The remaining figures show the plots of categorical features and their behavior.







**Figure 13.** Plot of Age\_bucket by Ethnicity




**Figure 14.** Plot of Tscore\_Bucket\_Prior\_Ntm by Risk\_Segment\_Prior\_Ntm




**Figure 15.** Plot of Injectable\_Experience\_During\_Rx by Gender




**Figure 16.** Plot of Age\_Bucket by Gender




**Figure 17.** Plot of Region by Ethnicity




**Figure 18.** Plot of Adherent flag by Ethnicity




**Figure 19.** Plot of Injectable\_Experience\_During\_Rx by Risk\_Segment\_During\_Rx



**Figure 20.** Plot of Gender by Adherent flag



**Figure 21.** Plot of Gender by Ethnicity



**Figure 21.** Plot of Injectable\_Experience\_During\_Rx by Ethnicity

### c. Categorical Comparisons

- **Ethnicity × Age\_Bucket:** Not-Hispanic individuals dominate the >75 years age group.
- **Tscore\_Bucket\_Prior\_Ntm × Risk\_Segment\_Prior\_Ntm:** The VLR\_LR group generally presents T-scores > -2.5.
- **Injectable\_Experience\_During\_Rx × Gender:** Female patients show the highest

proportion with prior injectable experience.

- **Age\_Bucket × Gender:** Female patients dominate across all age categories.
- **Adherent\_Flag × Ethnicity:** Not-Hispanic individuals are the most adherent.
- **Gender × Ethnicity:** The majority of female patients are Not-Hispanic.

### **3. Deductions and Insights**

1. Gender bias is evident, with female patients dominating across all variables, possibly reflecting differences in health-seeking behavior or disease prevalence.
2. Non-persistence increases with age (>75 years), likely due to comorbidities, cognitive decline, or complex regimens, with the potential majority being females.
3. Adherence does not guarantee persistence, indicating a gap between short-term compliance and sustained treatment.
4. Regional and ethnic disparities (Midwest and Non-Hispanic dominance) may reflect socioeconomic or healthcare accessibility factors.
5. Patients with low bone density (T-score  $\leq -2.5$ ) are more engaged but still experience non-persistence, potentially due to side effects or treatment fatigue.

### **4. Summary**

The analysis reveals consistent demographic and behavioral patterns influencing drug persistency flag. Females, Non-Hispanic patients, older adults, and those in the Midwest constitute the majority of the patient population. While adherence rates are initially high, persistence over time remains a challenge, especially among older patients. It also suggests that females are the gender category who are highly non-persistent.

### **5. Recommendations**

1. Implement targeted engagement programs for older adults with the focus on female non-Hispanics.
2. Develop culturally and regionally tailored communication strategies, focusing on the Midwest and Non-Hispanic populations.
3. Introduce behavioral adherence tools, such as mobile reminders or pharmacist counseling for female non-Hispanics.
4. Provide persistence-focused training for OB/GYN and primary care providers.

